Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-aventis hails positive trends in third quarter

Sanofi-aventis hails positive trends in third quarter

1st November 2010

Sanofi-aventis has noted its progress towards a number of business and clinical targets during the third quarter of 2010.

The pharmaceutical company's net sales for the three months increased by 5.7 percent year-on-year on a reported basis to 7.8 billion euros (6.8 billion pounds), taking its total for 2010 so far to just under 23 billion euros.

Sanofi-aventis highlighted the better-than-expected US launch performance of Jevtana as a key contributor, while vaccines, generics and consumer health products also showed strong levels of growth.

The firm has also been able to progress the clinical development of promising new drugs lixisenatide and teriflunomide, while continuing with its ongoing cost reduction programme.

Christopher Viehbacher, chief executive officer of Sanofi-aventis, said: "Tight cost control and good performance of growth platforms have allowed the group to slightly raise its guidance for 2010."

Last month, the company formed a new partnership with Harvard University, which will see the organisations ally on a number of collaboratively-chosen biomedical research initiatives.ADNFCR-8000103-ID-800208155-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.